title: Tysabri withdrawal calls entire class into question.
authors.forename: Emily
authors.initials: E
authors.lastname: Singer
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D004335:Drug and Narcotic Control; D039441:Integrin alpha4 / Q000187:drug effects; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab; D011358:Product Surveillance, Postmarketing
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D039441:Integrin alpha4